Home showing
 

Keywords :   


Tag: showing

Mercks Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus

2016-06-13 16:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Mercks investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-334-4688orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: to showing met primary

 

Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

2016-06-11 17:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily). Language: English Contact: Merck Media Contacts:Doris Li, 908-246-5701orKristen Drake, 908-334-4688orMerck Investor Contact:Justin Holko, 908-740-1879orPfizer Media Contact:Steve Danehy, 212-733-1538orPfizer Investor Contact:Ryan Crowe, 212-733-8160 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more

Tags: with type showing met

 
 

AB Graphic showing the power of partnerships in digital finishing

2016-06-02 15:04:00| Label and Narrow Web Breaking News

Drupa visitors can view the Digicon 3000 at the HP booth both in- and off-line alongside the HP Indigo 20000.

Tags: power digital showing graphic

 

NFU Concerned Over New Report Showing Additional Financial Strain in Farm Country

2016-04-27 22:24:25| National Farmers Union

FOR IMMEDIATE RELEASE April 27, 2016 Contact: Andrew Jerome, 202-314-3106 ajerome@nfudc.org WASHINGTON (April 27, 2016) Farm-sector lending volumes remain well above historic averages, according to a report released earlier this week from the Federal Reserve Bank of Kansas City, and the National Farmers Union (NFU) is viewing the new report with concern given the struggling farm

Tags: report additional country showing

 

Gallus: commitment to digital showing strong results

2016-04-22 21:53:00| Label and Narrow Web Breaking News

The Swiss press maker has announced two more sales of the Gallus Labelfire digital label printing system.

Tags: results digital showing strong

 

Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »